Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Global Fibrate Drugs Market Report 2024: A $5.14 Billion Market by 2034, Rising from S2.95 Billion in 2023

      Research and Markets Logo

      News provided by

      Research and Markets

      Mar 11, 2024, 12:30 ET

      Share this article

      Share this article


      DUBLIN, March 11, 2024 /PRNewswire/ -- The "Global Fibrate Drugs Market by Drug Type, by Product Type, by Distribution Channel, and By Region" report has been added to  ResearchAndMarkets.com's offering.

      The global fibrate drugs market size was estimated to be USD 2.95 billion in 2023 and is expected to reach USD 5.14 billion by 2034 with a CAGR of 5.16% during the forecast period 2024-2034. The rising burden of cardiovascular diseases, increasing awareness of the benefits of fibrates, development of new and improved fibrates, government initiatives for cardiovascular health, and strategic collaborations and partnerships will drive market growth.

      Since fibrate medications are frequently given to treat cardiovascular disorders including hyperlipidemia and atherosclerosis, their increasing prevalence may be the primary driver of the market for fibrate pharmaceuticals. The demand for fibrate medications may rise as a result of government health programs designed to lessen the burden of cardiovascular illnesses by raising awareness of and treating problems like dyslipidemia.

      By drug type, the fenofibrate segment accounted for the highest revenue-grossing segment in the global fibrate drugs market in 2023 owing to the compound's well-established efficacy in lowering triglycerides and increasing high-density lipoprotein (HDL) cholesterol levels, coupled with its widespread prescription for the management of dyslipidemia and cardiovascular risk factors. Additionally, the fenofibric acid derivatives segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of these derivatives for their enhanced bioavailability and improved pharmacokinetic profiles compared to traditional fenofibrate formulations.

      By product type, the generics segment accounted for the highest revenue-grossing segment in the global fibrate drugs market in 2023 owing to the expiration of key patents for several branded fibrate medications, leading to an influx of cost-effective generic alternatives into the market. For instance, Mylan N.V. received FDA clearance in December 2023 for its new generic fenofibrate extended-release tablets, providing patients with an affordable option. Additionally, the branded fibrates segment is predicted to grow at the fastest CAGR during the forecast period owing to the continuous innovation and introduction of novel formulations by pharmaceutical companies, aimed at addressing specific patient needs and improving treatment outcomes.

      By distribution channel, the retail pharmacies segment accounted for the highest revenue-grossing segment in the global fibrate drugs market in 2023 owing to the widespread accessibility and convenience offered to patients for obtaining prescription medications. For instance, Teva Pharmaceutical Industries Ltd. introduced a new combination medication including fenofibrate and ezetimibe in July 2023 to treat patients with excessive triglycerides and cholesterol, broadening its selection of generic fibrates. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend of digital healthcare adoption, the convenience of online prescription orders, and the expanding e-commerce landscape.

      The North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high prevalence of cardiovascular diseases, and the widespread adoption of fibrate drugs in the management of lipid disorders.

      Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of cardiovascular diseases, a rising geriatric population, and the ongoing efforts to improve healthcare infrastructure. 

      This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.

      Report Scope:

      • Base Year: 2023
      • Forecast Period: 2024-2034
      • Study Coverage
      • Market Forecast by Drug Type, Product Type, and Distribution Channel
      • Market Forecast for 5 Regions and 17+ Countries
        • North America (U.S. and Canada)
        • Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
        • Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
        • Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
        • MEA (South Africa, GCC, Rest of MEA)
      • Company Profiles of the Top 10+ Major Market Players

      Key Topics Covered:

      1. Research Methodology

      2. Introduction
      2.1. Market Definition
      2.2. Global Fibrate Drugs Market Overview

      3. Executive Summary

      4. Market Environment Analysis
      4.1. Porter's 5 Forces Analysis
      4.2. PESTEL Analysis
      4.3. SWOT Analysis

      5. Market Dynamics

      6. COVID-19 Impact Analysis

      7. Fibrate Drugs Market: Drug Type Estimates & Trend Analysis
      7.1. Drug Type Segment Opportunity Analysis
      7.2. Clofibrate
      7.3. Gemfibrozil
      7.4. Fenofibrate
      7.5. Others

      8. Fibrate Drugs Market: Product Type Estimates & Trend Analysis
      8.1. Product Type Segment Opportunity Analysis
      8.2. Branded
      8.3. Generics

      9. Fibrate Drugs Market: Distribution Channel Estimates & Trend Analysis
      9.1. Distribution Channel Segment Opportunity Analysis
      9.2. Hospital Pharmacy
      9.3. Retail Pharmacy
      9.4. Online Pharmacy

      10. Regional Market Analysis
      10.1. Regional Market Opportunity Analysis

      11. North America Fibrate Drugs Market

      12. Europe Global Fibrate Drugs Market

      13. Asia Pacific Global Fibrate Drugs Market

      14. Latin America Global Fibrate Drugs Market

      15. MEA Global Fibrate Drugs Market

      16. Competitor Analysis
      16.1. Company Market Share Analysis, 2023
      16.2. Major Recent Developments

      17. Company Profiles

      • Pfizer
      • AbbVie
      • AstraZeneca
      • Mylan
      • Teva Pharmaceutical Industries
      • Novartis
      • Sanofi
      • GlaxoSmithKline
      • Sun Pharmaceutical Industries
      • F. Hoffmann-La Roche
      • Bristol Myers Squibb
      • Merck
      • Abbott Laboratories
      • Daiichi Sankyo
      • Limited
      • Lupin.

      For more information about this report visit https://www.researchandmarkets.com/r/rtdbo3

      About ResearchAndMarkets.com
      ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

      Media Contact:

      Research and Markets
      Laura Wood, Senior Manager
      [email protected] 
       
      For E.S.T Office Hours Call +1-917-300-0470
      For U.S./CAN Toll Free Call +1-800-526-8630
      For GMT Office Hours Call +353-1-416-8900
       
      U.S. Fax: 646-607-1907
      Fax (outside U.S.): +353-1-481-1716

      Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

      SOURCE Research and Markets

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.